期刊
CURRENT OPINION IN PHARMACOLOGY
卷 16, 期 -, 页码 116-121出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2014.05.005
关键词
-
资金
- Biotechnology and Biological Sciences Research Council [BB/D014379/1] Funding Source: researchfish
- Medical Research Council [MR/K006312/1] Funding Source: researchfish
- BBSRC [BB/D014379/1] Funding Source: UKRI
- MRC [MR/K006312/1] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/D014379/1] Funding Source: Medline
- Medical Research Council [MR/K006312/1] Funding Source: Medline
Age-related loss of muscle mass and function, termed sarcopenia, is a catastrophic process, which impacts severely on quality of life of older people. The mechanisms underlying sarcopenia are unclear and the development of optimal therapeutic interventions remains elusive. Impaired regenerative capacity, attenuated ability to respond to stress, elevated reactive oxygen species production and low-grade systemic inflammation are all key contributors to sarcopenia. Pharmacological intervention using compounds such as 17AAG, SS-31 and Bimagrumab or naturally occurring polyphenols to target specific pathways show potential benefit to combat sarcopenia although further research is required, particularly to identify the mechanisms by which muscle fibres are completely lost with increasing age.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据